Too many loose ends, no solid results, no revenue

Too many loose ends, no solid results, no revenue , no reliable timelines....... just "exciting" talk is not enough to convince the market/reasonable funding or give Management the benefit of the doubt.........another reason for toxic funding. China deal risky imo.......potential 400mil .......is that before or after they will own vaccine IP? More acquisitions , ongoing litigation , unknown IPO target dates and the list goes on and on.........funding will be gone quickly if no rev stream or pps increase with positive news.